ReviewPituitary2023
How to manage intolerance to dopamine agonist in patients with prolactinoma.
Review in Pituitary, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 20 citations in OpenAlex.
- Chinese consensus on the diagnosis and treatment of prolactinomas (2025 edition).Chinese neurosurgical journal · 2026Review
- Cabergoline Induced Pathological Gambling in an Adolescent with ProlactinomaJournal of clinical research in pediatric endocrinology · 2026Article
- Somatostatin 5 receptor expression in prolactinomas: Is there a role for Pasireotide in the management of prolactinomas?Pituitary · 2025Article
- Dopamine D1 Receptor Contributes to Glucocorticoid-Associated Osteonecrosis of Femoral Head Protection Through the ATF3/CHOP Axis to Inhibit Osteoblastic Apoptosis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- A Narrative Review of Surgery for Prolactinomas: Considerations and Controversies.Journal of clinical medicine · 2025Review
- The Effect of HIF-2International journal of inflammation · 2025Review
- A multicenter study of clinical outcomes and volumetric trends in suspected microprolactinomas.Neurosurgical review · 2024Article
- Feasibility of Early Surgical Treatment for Adolescent Patients with Prolactinoma: A Case Report and Literature Review.Medicina (Kaunas, Lithuania) · 2024Review
- Aromatase inhibitors as a therapeutic strategy for male prolactinoma resistant to dopamine agonists: a retrospective cohort study and literature review.Journal of endocrinological investigation · 2024Review
- Ropinirole for the Treatment of Hyperprolactinemia: A Dose-Escalation Study of Efficacy and Tolerability.The Journal of clinical endocrinology and metabolism · 2024Article
- Diagnosis and management of prolactin-secreting pituitary adenomas: a Pituitary Society international Consensus Statement.Nature reviews. Endocrinology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeDopamine agonists (DA) are the gold-standard for prolactinoma and hyperprolactinemia treatment. Intolerance to DA leading to drug drop out occurs in 3 to 12% of cases. We provide here a review of published data about DA intolerance and present a case report concerning the use of intravaginal cabergoline.
methodsWe review the literature on the definition, the pathogenesis, frequency and management of DA intolerance. In addition, the review provides strategies to enhance tolerability and avoid precocious clinical treatment withdrawal.
resultsCabergoline is often cited as the most tolerable DA and its side effects tend to ameliorate within days to weeks. Restarting the same drug at a lower dose or switching to another DA can be used in cases of intolerance. The vaginal route can be tried specifically if there are gastrointestinal side effects in the oral administration. Symptomatic treatment could be attempted, although mainly based on a strategy used in other diseases.
conclusionsDue to limited data, no guidelines have been developed for the management of intolerance in DA treatment. The most frequent management is to perform transsphenoidal surgery. Nevertheless, this manuscript provides data derived from published literature and expert opinion, suggesting new approaches to this clinical issue.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.